HEPZATO's commercial trajectory in uveal melanoma tests whether regional hepatic perfusion can sustain profitability and expand into mCRC and mBC

Bull

A positive outcome would show meaningful improvements in hepatic response rate, progression-free survival, or overall survival in liver-dominant mCRC patients treated with HEPZATO plus SOC chemotherapy, providing the clinical foundation for a regulatory submission in a vastly larger addressable market than uveal melanoma. Demonstrating durable liver-directed control in mCRC would validate the platform's commercial scalability and support a significant re-rating of the revenue growth trajectory beyond current uveal melanoma volumes.

Bear

The most likely failure mode is insufficient differentiation from systemic chemotherapy alone — if hepatic response rates or PFS improvements are modest, regulators and oncologists may not view the procedural complexity and toxicity burden of isolated hepatic perfusion as justified in mCRC, where systemic regimens like FOLFOX/FOLFIRI plus biologics already achieve reasonable liver disease control. Additional risks include high rates of grade 3+ adverse events limiting patient eligibility and competing liver-directed options eroding the clinical rationale for HEPZATO in this setting.